Plecanatide lead drug: GC-C Receptor Agonist

Plecanatide (SP-304)

A patented drug candidate that targets GC-C receptors in the GI tract. Plecanatide is being developed to treat GI disorders, including chronic constipation and IBS-C. The drug candidate completed its initial Phase I safety trial in volunteers, and completed a Phase IIa clinical trial in chronic constipation patients in 2010.

1. ✓Plecanatide - new class of drug with only one competitor
   

2. ✓Strong IP position
   

3. ✓Good clinical proof-of-principle for the class
   

4. ✓Plecanatide targeted towards huge and under-served market
   

For ongoing and completed trials see descriptions at www.clinicaltrials.gov